Patient Advocates Warn Against New Insurance and Pharmacy Benefit Manager Policy That Increases Patient Out-of-Pocket Drug Costs Posted

By Christina Jensen   As Open Enrollment Begins, Beneficiaries who Rely on Copay Coupons Must Consider this New Policy When Selecting a Health Plan The AIDS Institute, Arthritis Foundation, and National Organization for Rare Disorders (NORD) hosted a press briefing on a harmful new health insurance and Pharmacy Benefit Manager…...

Read more

Computer Technology to Help Diagnose Vasculitis Earlier? Rheumatologist Antoine Sreih, MD is Working On It.

By Ed Becker, Director of Marketing and Communications Despite advances made in the research, understanding, and treatment of vasculitis, the reality is that delay of diagnosis continues to be a critical issue. As a rheumatologist, Antoine Sreih, MD, says that every day he sees the unfortunate result when patients are…...

Read more

Vasculitis Foundation Board Welcomes New Members During Its Fall 2018 Meeting

l-r: Suzanne DePaolis, Peter Grayson, MD, Jason Springer, MD, George Casey, Karen Hirsch, Rhonda Johnson Byrd, Victor James, and Don Nagle   By Ed Becker The VF held its annual membership meeting on Thursday, October 18, 2018 in Chicago. Karen Hirsch, VF President, reported on the organization’s accomplishments and recognized…...

Read more

Organization Supports Vasculitis Patients and Research in the UK and Scotland

Lauren with her parents, Grant and Adrienne Currie   By Ed Becker One of the most important vasculitis awareness and advocacy organizations in Scotland and throughout the United Kingdom is the Lauren Currie Twilight Foundation (LCTF). Grant and Adrienne Currie established the LCTF in memory of their daughter, Lauren, who…...

Read more

FDA Approves Label Update for Genentech’s Rituxan® (rituximab) in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

October 19, 2018 — Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) who…...

Read more